Synapse - Robert Motzer

Results (1247)

Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

Meeting Abstract

Motzer, R. J.; Russo, P.; Gruenwald, V.; Tomita, Y.; Zurawski, B.; Parikh, O. A.; Buti, S.; Barthelemy, P.; Goh, J. C. H.; Ye, D.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

Meeting Abstract

Choueiri, T. K.; Powles, T. B.; Albiges, L.; Burotto, M.; Szczylik, C.; Zurawski, B.; Riuz, E. Y.; Maruzzo, M.; Zaizar, A. S.; Fein, L. E.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

Meeting Abstract

Porta, C. G.; Eto, M.; Motzer, R. J.; De Giorgi, U. F. F.; Buchler, T.; Basappa, N. S.; Vidal, M. J. M.; Tjulandin, S.; Park, S. H.; Melichar, B.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Association between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced first-line (1L) renal cell carcinoma (aRCC): Exploratory analyses from CheckMate 9ER (CM 9ER)

Meeting Abstract

Cella, D.; Porta, C. G.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Rodriguez, C. S.; Choueiri, T. K.; Motzer, R. J.
Annals of Oncology (2022)

Fulltext@MSK | Save

Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC)

Meeting Abstract

Escudier, B.; Motzer, R. J.; Dyer, M.; May, J. R.; Ejzykowicz, F.; Kurt, M.; Lee, C. W.; Wang, P.; Testa, E.; Sharpe, D. J.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal Article

Rini, B. I.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; George, S.; Powles, T.; Donskov, F.; Tykodi, S. S.; Pal, S. K.; more...
Journal for ImmunoTherapy of Cancer (2022)

Fulltext@MSK | Save

Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape

Journal Article

Golkaram, M.; Kuo, F.; Gupta, S.; Carlo, M. I.; Salmans, M. L.; Vijayaraghavan, R.; Tang, C.; Makarov, V.; Rappold, P.; Blum, K. A.; more...
Genome Medicine (2022)

Fulltext@MSK | Save

Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade

Journal Article

Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
Clinical Cancer Research (2022)

Fulltext@MSK | Save

Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study

Meeting Abstract

Voss, M. H.; Powles, T.; McGregor, B. A.; Porta, C.; Grünwald, V.; Merchan, J. R.; Rolland, F.; Maroto-Rey, P.; Goh, J. C.; Xing, D.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER

Meeting Abstract

Suárez, C.; Choueiri, T. K.; Burotto, M.; Powles, T.; Bourlon, M. T.; Shah, A. Y.; Tomita, Y.; Bedke, J.; Zhang, J.; Simsek, B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save